Through the glass darkly: intraepithelial neoplasia, top‐down differentiation, and the road to ovarian cancer
- 12 November 2013
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 231 (4), 402-412
- https://doi.org/10.1002/path.4263
Abstract
It is currently hoped that deaths from extra-uterine high-grade serous cancer (HGSC) will be reduced via opportunistic salpingectomy in healthy women. Accumulated data implicate the fimbria as a site of origin and descriptive molecular pathology and experimental evidence strongly support a serous carcinogenic sequence in the Fallopian tube. Both direct and indirect (surrogate') precursors suggest that the benign tube undergoes important biological changes after menopause, acquiring abnormalities in gene expression that are often shared with malignancy, including PAX2, ALDH1, LEF1, RCN1, RUNX2, beta-catenin, EZH2, and others. However, the tube can be linked to only some HGSCs, recharging arguments that nearby peritoneum/ovarian surface epithelium (POSE) also hosts progenitors to this malignancy. A major sticking point is the difference in immunophenotype between POSE and Mullerian epithelium, essentially requiring mesothelial to Mullerian differentiation prior to or during malignant transformation to HGSC. However, emerging evidence implicates an embryonic or progenitor phenotype in the adult female genital tract with the capacity to differentiate, normally or during neoplastic transformation. Recently, a putative cell of origin for cervical cancer has been identified in the squamo-columnar (SC) junction, projecting a model whereby Krt7+ embryonic progenitors give rise to immunophenotypically distinct progeny under stromal influences via top down' differentiation. Similar differentiation can be seen in the endometrium with a parallel in juxtaposed mesothelial and Mullerian differentiation in the ovary. Abrupt mesothelial-Mullerian transitions remain to be proven, but would explain the rapid evolution, short asymptomatic interval, and absence of a defined epithelial starting point in many HGSCs. Resolving this question will require accurately distinguishing progenitor from progeny tumour cells in HGSC and pinpointing where initial transformation and trans-differentiation occur, whether in the tube or POSE. Both will be critical to expectations from prophylactic salpingectomy and future approaches to pelvic serous cancer prevention. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 74 references indexed in Scilit:
- Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospectsVaccine, 2013
- Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot projectThe Lancet Oncology, 2012
- Residual Embryonic Cells as Precursors of a Barrett's-like MetaplasiaCell, 2011
- Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivoOncogene, 2011
- Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry dataThe Lancet, 2010
- Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tubeThe Journal of Pathology, 2010
- Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesisOncogene, 2009
- The Li–Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tubeThe Journal of Pathology, 2009
- Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicityGynecologic Oncology, 2009
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutationsGynecologic Oncology, 2008